NEWARK, Del, March 08, 2023 (GLOBE NEWSWIRE) -- The global Cancer Vaccine Market is expected to grow significantly in the coming years, according to a new report published by Future Market Insights. The report predicts that the market will grow at a compound annual growth rate (CAGR) of 12% from 2023 to 2033, reaching a value of US$ 24.22 Billion by the end of the forecast period. Cancer remains one of the most significant health challenges of our time, with millions of people diagnosed with the disease every year.
The cancer vaccine market is driven by factors such as increasing incidence of cancer, growing awareness about cancer vaccines, and government initiatives to promote cancer research and development. One of the key factors driving the growth of the cancer vaccine market is the increasing incidence of cancer worldwide. This is due to a variety of factors, such as aging populations, changing lifestyle patterns, and environmental factors. As the incidence of cancer continues to rise, there is a greater need for effective cancer treatments, including cancer vaccines.
Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16768
Government initiatives are also playing a significant role in driving the growth of the cancer vaccine market. Governments around the world are investing heavily in cancer research and development, which has led to increased funding for cancer vaccine development and clinical trials. For example, the US government has launched the Cancer Moonshot initiative, which aims to accelerate cancer research and improve cancer treatment and prevention.
Key Takeaways from the Market Study
- The market for cancer vaccines expanded at a 9% CAGR from 2018 to 2022.
- The market for cancer vaccines is anticipated to expand at a 12% CAGR from 2023 to 2033.
- The market for cancer vaccines is anticipated to reach US$ 24.22 billion by 2033.
- Recombinant cancer vaccines have the biggest market share, according to the Future Market Insights research.
- For the market for cancer vaccines, North America is anticipated to hold a 40% market share.
- With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Cancer Vaccines.” says an FMI analyst
Contact our Market Research Specialist: https://www.futuremarketinsights.com/ask-question/rep-gb-16768
Market Competition
Key players in the market include companies such as Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Vaccinogen, Inc., F Hoffmann-La Roche AG, and OSE Immunotherapeutics, along with healthcare providers and technology companies among other global players.
- In January 2023, the U.K. government announced a collaboration with BioNTech, a German company, to trial potential vaccines for cancer and other illnesses, while campaigners cautioned that any breakthrough must remain affordable and accessible. Personalized mRNA therapies, including cancer vaccines that aim to activate the immune system against harmful cells, will be tested on cancer patients in England at both early and late stages. The therapies target active cancer cells and work to prevent their return. BioNTech will establish new research and development centers in the U.K., including a laboratory in Cambridge and a headquarters in London, and aim to supply 10,000 therapies to patients from September 2023 until the end of the decade.
The firm developed one of the most widely-distributed Covid-19 vaccines in collaboration with U.S. pharmaceutical firm Pfizer. The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Cancer Vaccines market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Technology, Treatment Method, Application & Region.
View Full Report@ https://www.futuremarketinsights.com/reports/cancer-vaccines-market
Key Segments Profiled in the Cancer Vaccines Industry Survey
Technology:
- Recombinant Cancer Vaccines
- Whole-cell Cancer Vaccines
- Viral Vector & DNA Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
Treatment Method:
- Preventive Vaccine
- Therapeutic Vaccine
Application:
- Prostate Cancer
- Cervical Cancer
- Other Applications
Table of Content
1. Executive Summary | Cancer Vaccines Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Buy This Report: https://www.futuremarketinsights.com/checkout/16768
Have a Look at Related Research Reports of Healthcare Domain:
Specialty Medical Chairs Market Size - Specialty Medical Chairs Market was held at around US$ 3.3 Billion in 2023 and is expected to grow with a CAGR of 8.7% from 2023 to 2033.
Burns Treatment Market Growth - The global Burns Treatment Market is expected to garner a market value of US$ 1.2 Billion in 2023 and is expected to accumulate a market value of US$ 2.59 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033.
Cerebral Aneurysm Management Market Demand - The global cerebral aneurysm management market is expected to garner a market value of US$ 1.56 Billion in 2023 and is expected to accumulate a market value of US$ 2.98 Billion by registering a CAGR of 6.7% in the forecast period 2023-2033.
Carrier Screening Market Trends - The size of the global carrier screening market was estimated in 2023 at US$ 1,343.40 million, and it is anticipated to exhibit a CAGR of 12.4% from 2023 to 2033. By 2033, the market is expected to be worth US$ 4,323.84 million.
Antibody-mediated Rejection Prevention Market Forecast - The global antibody-mediated rejection prevention market is expected to be valued at US$ 89 million in 2023 and is projected to rise at a CAGR of 16% from 2023 to 2033.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
